文献速递血液淋巴病理

髓系基因检测面板的设计与诊断效能评估

Designing Myeloid Gene Panels.
PubMed 文献 · Arch Pathol Lab Med · 2022-01-01

该研究回顾性分析了185例已知或疑似慢性髓系肿瘤(CMN)患者,使用包含Association for Molecular Pathology(AMP)核心34基因的62基因二代测序面板检测。核心34基因对至少1个强/潜在临床意义变异的诊断效能为158/185(85.4%),62基因面板为160/185(86.5%);核心34基因对至少2个此类变异的诊断效能为107/185(57.8%),62基因面板为112/185(60.5%)。核心34基因的不明意义变异检出率为49/185(26.5%),62基因面板为76/185(41.1%)。作者推荐在AMP核心34基因基础上增加CUX1、DDX41、ETNK1、RIT1和SUZ12用于CMN常规评估。

要点

  • AMP核心34基因集在CMN中诊断效能高,至少1个强/潜在临床意义变异检出率85.4%。
  • 62基因面板较核心34基因仅轻微提高异常检出率(86.5% vs 85.4%),但不明意义变异检出率更高(41.1% vs 26.5%)。
  • 推荐在AMP核心34基因基础上增加CUX1、DDX41、ETNK1、RIT1和SUZ12用于CMN常规评估。

核心结论

  • AMP推荐的核心34基因集在慢性髓系肿瘤中具有高诊断效能。
  • 增加所选额外基因可轻微提高异常结果率,同时增加不明意义变异检出。
  • 推荐在AMP核心34基因基础上增加CUX1、DDX41、ETNK1、RIT1和SUZ12用于CMN常规评估。

研究设计与样本

  • 回顾性分析185例已知或疑似CMN患者,使用包含全部34个核心基因的62基因二代测序面板检测。

主要发现

  • 核心34基因检出至少1个强/潜在临床意义变异的诊断效能为158/185(85.4%),62基因面板为160/185(86.5%)。
  • 核心34基因检出至少2个强/潜在临床意义变异的诊断效能为107/185(57.8%),62基因面板为112/185(60.5%)。
  • 核心34基因检出不明意义变异为49/185(26.5%),62基因面板为76/185(41.1%)。

关键数值与推荐

  • AMP CMN工作组推荐核心34基因集作为评估CMN的最低目标列表。
  • 推荐在AMP核心34基因基础上增加CUX1、DDX41、ETNK1、RIT1和SUZ12用于CMN常规评估。

临床怎么用

  • 在CMN评估中可采用AMP核心34基因集作为最低目标列表。
  • 若需提高异常检出率,可在核心34基因基础上增加CUX1、DDX41、ETNK1、RIT1和SUZ12,但需注意不明意义变异检出增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: Next-generation sequencing studies are increasingly used in the evaluation of suspected chronic myeloid neoplasms (CMNs), but there is wide variability among laboratories in the genes analyzed for this purpose. Recently, the Association for Molecular Pathology CMN working group recommended a core 34-gene set as a minimum target list for evaluation of CMNs. This list was recommended based on literature review, and its diagnostic yield in clinical practice is unknown. OBJECTIVE.—: To determine the diagnostic yield of the core 34 genes and assess the potential impact of including selected additional genes. DESIGN.—: We retrospectively reviewed 185 patients with known or suspected CMNs tested using a 62-gene next-generation sequencing panel that included all 34 core genes. RESULTS.—: The Association for Molecular Pathology's core 34 genes had a diagnostic yield of 158 of 185 (85.4%) to detect at least 1 variant with strong/potential clinical significance and 107 of 185 (57.8%) to detect at least 2 such variants. The 62-gene panel had a diagnostic yield of 160 of 185 (86.5%) and 112 of 185 (60.5%), respectively. Variants of unknown significance were identified in 49 of 185 (26.5%) using the core 34 genes versus 76 of 185 (41.1%) using the 62-gene panel. CONCLUSIONS.—: This study demonstrates that the Association for Molecular Pathology-recommended core 34-gene set has a high diagnostic yield in CMNs. Inclusion of selected additional genes slightly increases the rate of abnormal results, while also increasing the detection of variants of unknown significance. We recommend inclusion of CUX1, DDX41, ETNK1, RIT1, and SUZ12 in addition to the Association for Molecular Pathology's 34-gene core set for routine evaluation of CMNs.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Zhao F, Bosler DS, Cook JR, et al. Designing Myeloid Gene Panels. Arch Pathol Lab Med. 2022. PMID: 34784413. doi:10.5858/arpa.2021-0124-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。